Abstract:

Multi-gene testing in breast cancer and clinical significance        MA Rong*, WANG Jian-li. *Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan 250012, China
Corresponding author: MA Rong, E-mail: marongw2000@163.com
Abstract    Multi-gene testing (MGT) can provide information that could assist prognosis prediction and therapeutic decision-making in ER-positive cancers. Recently, many MGT models have been endorsed by the American Society of Clinical Oncology, St.Gallen and National Comprehensive Cancer Network guidelines. A panel of clinically validated MGT models including IHC4 score, MammaPrint, PAM50, Oncotype DX, Genomic grade index, Breast Cancer Index, EndoPredict and homologous recombination deficiency score are seven typical MGT, which can predict the risk of metastasis and recurrence and guide the therapy of breast cancer.

Key words: multi-gene testing, breast cancer, prognosis

摘要：

多基因检测对于乳腺癌的预后判断和治疗方案选择具有重要的参考意义，特别是对雌激素受体阳性病人。近年来一些多基因诊断模型被美国临床肿瘤学会（ASCO）、圣加伦标准、美国国家综合癌症网络（NCCN）等多个权威乳腺癌诊疗指南所采用，并开展了临床应用。IHC4评分、MammaPrint、PAM50、Oncotype DX、Genomic grade index、Breast Cancer Index、EndoPredict和同源重组缺陷评分为7个代表性的乳腺癌多基因检测方法，不但可以用于转移复发生存风险的预测，还可以对治疗有指导意义。

关键词: 多基因检测, 乳腺癌, 预后